Literature DB >> 12427307

Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2.

Michael H Kershaw1, Gang Wang, Jennifer A Westwood, Russell K Pachynski, H Lee Tiffany, Francesco M Marincola, Ena Wang, Howard A Young, Philip M Murphy, Patrick Hwu.   

Abstract

T-cell-based immunotherapies provide a promising means of cancer treatment although durable antitumor responses are infrequent. A potential reason for these shortcomings may lie in the observed lack of trafficking of specific T cells to tumor. Our increasing knowledge of the process of trafficking involving adhesion molecules and chemokines affords us the opportunity to intervene and correct deficiencies in this process. Chemokines can be expressed by a range of tumors and may serve as suitable targets for directing specific T cells toward tumor. We initially sought to identify which chemokines were produced by a range of human tumor cell lines, and which chemokines and chemokine receptors were expressed by cultured T cells. We identified two chemokines: Growth-Regulated Oncogene-alpha (Gro-alpha; CXCL1) and Regulated on Activation Normal T Cell-Expressed and Secreted (RANTES; CCL5), to be secreted by several human tumor cell lines. Expression was also detected in fine-needle aspirates of melanoma from patients. In addition, we determined the expression of several chemokine receptors on cultured human T cells including CCR1, CCR2, CCR4, CCR5, CXCR3, and CXCR4. Cultured, activated human T cells expressed the chemokines lymphotactin (XCL1), RANTES, macrophage inflammatory protein-1 alpha (MIP-1 alpha; CCL3) and MIP-1 beta (CCL4), but no appreciable Gro-alpha. In a strategy to direct T cells toward chemokines expressed by tumors we chose Gro-alpha as the target chemokine because it was produced by tumor and not by T cells themselves. However, T cells did not express the receptor for Gro-alpha, CXCR2, and therefore, T cells were transduced with a retroviral vector encoding CXCR2. Calcium ion mobilization, an important first step in chemokine receptor signaling, was subsequently demonstrated in transduced T cells in response to Gro-alpha. In addition, Gro-alpha was chemotactic for T cells expressing CXCR2 in vitro toward both recombinant protein and tumor-derived chemokine. Interestingly we demonstrate, for the first time, that Gro-alpha was able to induce interferon-gamma (IFN-gamma) secretion from transduced T cells, thereby extending our knowledge of other potential functions of CXCR2. This study demonstrates the feasibility of redirecting the migration properties of T cells toward chemokines secreted by tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12427307     DOI: 10.1089/10430340260355374

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  117 in total

Review 1.  Advances in the treatment of metastatic melanoma: adoptive T-cell therapy.

Authors:  Chantale Bernatchez; Laszlo G Radvanyi; Patrick Hwu
Journal:  Semin Oncol       Date:  2012-04       Impact factor: 4.929

Review 2.  Cellular immunotherapy for malignant gliomas.

Authors:  Yi Lin; Hideho Okada
Journal:  Expert Opin Biol Ther       Date:  2016-07-29       Impact factor: 4.388

Review 3.  Adoptive immunotherapy for cancer: building on success.

Authors:  Luca Gattinoni; Daniel J Powell; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

4.  Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.

Authors:  Jennifer A Westwood; Mark J Smyth; Michele W L Teng; Maria Moeller; Joseph A Trapani; Andrew M Scott; Fiona E Smyth; Glenn A Cartwright; Barbara E Power; Dirk Hönemann; H Miles Prince; Phillip K Darcy; Michael H Kershaw
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

5.  WHO classification of myeloid neoplasms and leukemia.

Authors:  Hannes Wandt; Torsten Haferlach; Christian Thiede; Gerhard Ehninger
Journal:  Blood       Date:  2010-01-21       Impact factor: 22.113

6.  Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes.

Authors:  Yozo Nakazawa; Leslie E Huye; Gianpietro Dotti; Aaron E Foster; Juan F Vera; Pallavi R Manuri; Carl H June; Cliona M Rooney; Matthew H Wilson
Journal:  J Immunother       Date:  2009-10       Impact factor: 4.456

7.  Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.

Authors:  Nobuhiro Nishio; Iulia Diaconu; Hao Liu; Vincenzo Cerullo; Ignazio Caruana; Valentina Hoyos; Lisa Bouchier-Hayes; Barbara Savoldo; Gianpietro Dotti
Journal:  Cancer Res       Date:  2014-07-24       Impact factor: 12.701

Review 8.  Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.

Authors:  Maya Suzuki; Kevin J Curran; Nai-Kong V Cheung
Journal:  Pediatr Blood Cancer       Date:  2015-04-01       Impact factor: 3.167

9.  Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.

Authors:  Melinda Mata; Claudia Gerken; Phuong Nguyen; Giedre Krenciute; David M Spencer; Stephen Gottschalk
Journal:  Cancer Discov       Date:  2017-08-11       Impact factor: 39.397

10.  Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.

Authors:  Helena Harlin; Yuru Meng; Amy C Peterson; Yuanyuan Zha; Maria Tretiakova; Craig Slingluff; Mark McKee; Thomas F Gajewski
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.